Panelists conflicted about positive trial's ability to validate biomarker-guided switching ...

In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...

Please provide your email address to receive an email when new articles are posted on . In an interview with Healio, Kushner said these findings, presented at The Liver Meeting, suggest “perhaps ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses data from the phase 3 EPCORE FL-1 trial, presented at ...

But it doesn't always end there. At some point, you may need to switch treatments. The growing number of options to manage HR-positive/HER2-negative metastatic breast ...

Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities. In the second-line setting for ...

Socioeconomic disparities in pancreatic cancer treatment: The role of pre-diagnosis healthcare utilization. Best overall responses (BOR) of third or above line subgroup or ECOG PS 2-3 subgroup. third ...

Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes. In the second-line management of follicular lymphoma, ...